How to Camouflage a Virus: The Latest in Gene Therapy with Genine Winslow
Genine Winslow, the CEO and Co-founder of Chameleon Biosciences, a biotechnology company focused on safer, more effective gene therapies joins eHealth Radio and the Health News Channel.
Chameleon’s (patent pending) EVADER™ platform is helping to make it possible to treat people who previously could not be treated with gene therapy, especially children with genetic diseases such as severe Hemophilia B.
Listen to host Eric Dye & guests Genine Winslow discuss the following:
Obviously viruses are on everyone’s mind right now. The truth is that while viruses can be deadly such as in the case of COVID-19, gene therapy actually uses viruses as treatment vehicles for genetic diseases. Can you explain what it is about viruses that makes them ideal for treating genetic diseases?
As I understand it, Chameleon’s work focuses on treatments for people who can’t be treated with conventional gene therapies--why is it that some people, especially children, are untreatable?
Going into detail--back to COVID-19--the vaccines so many of us are getting are designed to prime our immune systems to help us detect and fight COVID-19. Chameleon’s work sounds like the opposite goal--to help viruses get past a person’s immune system multiple times. Talk about the science in that--where did the idea come from?
At Chameleon, you’ve developed an innovation called EVADER™. Can you explain (in simplified terms) what EVADER does to get around the issues you just described?
Obviously getting to market for something like EVADER is something that takes a lot of time and testing and funding. Can you tell us where Chameleon is in the process?
You’ve worked for many different groups as a scientist and now you run your own company. To all the managers and leaders out there, what is it that you would say scientists need in the workplace to be able to do their best work?
Genine Winslow is the CEO and co-founder of Chameleon Biosciences, a biotechnology company she founded in 2017 focused on safer, more effective gene therapies. At Chameleon, Genine combines her backgrounds in both immunology and gene therapy to engineer a next generation AAV based vector for systemic repeat dosing for children and adults who today cannot be treated with conventional gene therapies. Prior to Chameleon, Winslow has led gene therapy scientific initiatives at multiple companies including Audentes Therapeutics, BioMarin, BlueBird Bio, and Cell Genesys.